| Name | Vonafexor |
|---|---|
| Synonyms |
PLX007
YP001 4-chloro-5-[4-(2,6-dichlorobenzene-1- sulfonyl)piperazin-1-yl]-1-benzofuran-2-cboxylic acid 2-Benzofurancboxylic acid, 4-chloro-5-[4-[(2,6-dichlorophenyl)sulfonyl]-1-piperazinyl] Vonafexor, 10 mM in DMSO EYP-001 PXL007 NR1H4,HBV,FXR,EYP 001,Inhibitor,Vonafexor,EYP-001,inhibit,Hatitis B virus Vonafexor(EYP-001) 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-cboxylic acid 4-Chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)piperazin-1-yl)benzofuran-2-cboxylic acid |
| Description | Vonafexor (EYP001) is a selective FXR agonist with anti-HBV effects[1][2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.604±0.06 g/cm3(Predicted) |
|---|---|
| Boiling Point | 680.5±65.0 °C(Predicted) |
| Molecular Formula | C19H15Cl3N2O5S |
| Molecular Weight | 489.76 |
| Hazard Codes | Xn |
|---|